Literature DB >> 32031647

Association of Subclinical Hypothyroidism and Cardiovascular Disease With Mortality.

Kosuke Inoue1, Beate Ritz1,2, Gregory A Brent3,4, Ramin Ebrahimi5, Connie M Rhee6, Angela M Leung3,4.   

Abstract

Importance: Subclinical hypothyroidism is a common clinical entity among US adults associated in some studies with an increase in the risk of cardiovascular disease (CVD) and mortality. However, the extent to which CVD mediates the association between elevated serum thyrotropin (TSH) and mortality has not yet been well established or sufficiently quantified. Objective: To elucidate the extent to which subclinical hypothyroidism, elevated serum TSH and normal serum free thyroxine, or high-normal TSH concentrations (ie, upper normative-range TSH concentrations) are associated with mortality through CVD among US adults. Design, Setting, and Participants: This cohort study relied on representative samples of US adults enrolled in the National Health and Nutrition Examination Survey in 2001 to 2002, 2007 to 2008, 2009 to 2010, and 2011 to 2012 and their mortality data through 2015. Data were analyzed from January to August 2019. Main Outcomes and Measures: Cox proportional hazards regression models were used to investigate associations between the TSH concentration category (subclinical hypothyroidism or tertiles of serum TSH concentrations within the reference range; low-normal TSH, 0.34-1.19 mIU/L; middle-normal TSH, 1.20-1.95 mIU/L; and high-normal TSH, 1.96-5.60 mIU/L) and all-cause mortality. Mediation analysis was used within the counterfactual framework to estimate natural direct associations (not through CVD) and indirect associations (through CVD).
Results: Of 9020 participants, 4658 (51.6%) were men; the mean (SD) age was 49.4 (17.8) years. Throughout follow-up (median [interquartile range], 7.3 [5.4-8.3] years), serum thyroid function test results consistent with subclinical hypothyroidism and high-normal TSH concentrations were both associated with increased all-cause mortality (subclinical hypothyroidism: hazard ratio, 1.90; 95% CI, 1.14-3.19; high-normal TSH: hazard ratio, 1.36; 95% CI, 1.07-1.73) compared with the middle-normal TSH group. Cardiovascular disease mediated 14.3% and 5.9% of the associations of subclinical hypothyroidism and high-normal TSH with all-cause mortality, respectively, with the CVD mediation being most pronounced in women (7.5%-13.7% of the association) and participants aged 60 years and older (6.0%-14.8% of the association). Conclusions and Relevance: In this study, CVD mediated the associations of subclinical hypothyroidism and high-normal TSH concentrations with all-cause mortality in the US general population. Further studies are needed to examine the clinical benefit of thyroid hormone replacement therapy targeted to a middle-normal TSH concentration or active CVD screening for people with elevated TSH concentrations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32031647     DOI: 10.1001/jamanetworkopen.2019.20745

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  14 in total

Review 1.  Thyroid disorders and cardiovascular manifestations: an update.

Authors:  Stavroula A Paschou; Evanthia Bletsa; Panagiota K Stampouloglou; Vasiliki Tsigkou; Angeliki Valatsou; Katerina Stefanaki; Paraskevi Kazakou; Michael Spartalis; Eleftherios Spartalis; Evangelos Oikonomou; Gerasimos Siasos
Journal:  Endocrine       Date:  2022-01-15       Impact factor: 3.633

2.  Attaining biochemical euthyroidism early after total thyroidectomy in Graves' disease may lower long-term morbidity risk.

Authors:  Xiaodong Liu; Carlos K H Wong; Wendy W L Chan; Eric H M Tang; Yu Cho Woo; Shirley Y W Liu; Cindy L K Lam; Brian H H Lang
Journal:  BJS Open       Date:  2022-07-07

3.  Low HbA1c levels and all-cause or cardiovascular mortality among people without diabetes: the US National Health and Nutrition Examination Survey 1999-2015.

Authors:  Kosuke Inoue; Roch Nianogo; Donatello Telesca; Atsushi Goto; Vahe Khachadourian; Yusuke Tsugawa; Takehiro Sugiyama; Elizabeth Rose Mayeda; Beate Ritz
Journal:  Int J Epidemiol       Date:  2021-08-30       Impact factor: 7.196

Review 4.  L-T4 Therapy in the Presence of Pharmacological Interferents.

Authors:  Salvatore Benvenga
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-22       Impact factor: 5.555

5.  Delayed Follow-up Visits and Thyrotropin Among Patients With Levothyroxine During the COVID-19 Pandemic.

Authors:  Kosuke Inoue; Jaeduk Yoshimura Noh; Ai Yoshihara; Natsuko Watanabe; Masako Matsumoto; Miho Fukushita; Nami Suzuki; Ayako Hoshiyama; Takako Mitsumatsu; Ai Suzuki; Aya Kinoshita; Kentaro Mikura; Ran Yoshimura; Kiminori Sugino; Koichi Ito
Journal:  J Endocr Soc       Date:  2021-11-28

6.  Machine Learning Coronary Artery Disease Prediction Based on Imaging and Non-Imaging Data.

Authors:  Vassiliki I Kigka; Eleni Georga; Vassilis Tsakanikas; Savvas Kyriakidis; Panagiota Tsompou; Panagiotis Siogkas; Lampros K Michalis; Katerina K Naka; Danilo Neglia; Silvia Rocchiccioli; Gualtiero Pelosi; Dimitrios I Fotiadis; Antonis Sakellarios
Journal:  Diagnostics (Basel)       Date:  2022-06-14

7.  Specific impact of cardiovascular risk factors on coronary microcirculation in patients with subclinical hypothyroidism.

Authors:  Mirjana Stojković; Biljana Nedeljković-Beleslin; Milorad Tešić; Zoran Bukumirić; Jasmina Ćirić; Miloš Stojanović; Marija Miletić; Ana Đorđević-Dikić; Vojislav Giga; Branko Beleslin; Miloš Žarković
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

Review 8.  Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease.

Authors:  Laura Y Sue; Angela M Leung
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

9.  The Two Faces of Janus: Why Thyrotropin as a Cardiovascular Risk Factor May Be an Ambiguous Target.

Authors:  Johannes Wolfgang Dietrich; Rudolf Hoermann; John E M Midgley; Friederike Bergen; Patrick Müller
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-26       Impact factor: 5.555

10.  Prognostic Value of Normal Thyroid Stimulating Hormone in Long-Term Mortality in Patients With STEMI.

Authors:  Lijie Sun; Keling Xiao; Zupei Miao; Yinghua Zhang; Jin Si; Ning Shi; Haoyu Zhang; Ting Zhao; Jing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.